LCMS
Další informace
WebinářeO násKontaktujte násPodmínky užití
LabRulez s.r.o. Všechna práva vyhrazena. Obsah dostupný pod licencí CC BY-SA 4.0 Uveďte původ-Zachovejte licenci.
Pořadatel
C&EN
C&EN
Chemical & Engineering News (C&EN) je vlajkovým časopisem American Chemical Society, organizace s více než 157 000 členy ve více než 100 zemích. "Like" C&EN, pokud jste profesionál, který hledá novinky z chemie, nebo jste prostě fanouškem chemie.
Tagy
Akademie/Principy
LinkedIn Logo

Accelerating Drug Discovery: Enhanced Chemistry Strategies for NCEs, ADCs, and Emerging Modalities

ZÁZNAM | Proběhlo St, 17.9.2025
Připojte se k odborníkům společnosti Eurofins Discovery a objevte strategie chemického výzkumu založené na umělé inteligenci, které urychlují vývoj nových léčiv, od ADC přes degradéry až po malé molekuly.
Přejít na webinář
C&EN: Accelerating Drug Discovery: Enhanced Chemistry Strategies for NCEs, ADCs, and Emerging Modalities
C&EN: Accelerating Drug Discovery: Enhanced Chemistry Strategies for NCEs, ADCs, and Emerging Modalities

The need for efficient and innovative drug discovery chemistry strategies to support novel modalities like Degraders, ADCs (Antibody-Drug Conjugates), and other complex therapeutics has never been greater.

In this webinar, Eurofins Discovery’s global team of chemistry experts will share how integrated, AI-enhanced workflows and high-throughput methods are accelerating the development of robust candidates. Drawing on our proven expertise in medicinal, computational, synthetic, and analytical chemistry, we’ll explore how our streamlined, automation-driven approach enables the rapid delivery of potent, high-quality compounds, while ensuring IP protection and cost efficiency.

The session will highlight real-world applications of these capabilities, including the story of an A2A receptor program that progressed from early-stage discovery to preclinical candidate nomination for Parkinson’s Disease, and was later successfully repositioned for Immuno-Oncology. We’ll also explore how our chemistry strategies are enabling the development of complex modalities such as degraders and ADCs, demonstrating the scalability and precision of our approach across diverse therapeutic platforms.

Whether you're working on traditional small molecules or next-generation biologically targeted therapies, this session will help you identify practical strategies to reduce risk, enhance translational success, and accelerate your discovery pipeline.

Key Learning Objectives:
  • Leverage integrated chemistry platforms support to accelerate iteration and decision-making across modalities, including NCEs, ADCs, and hybrids
  • Apply innovative approaches to payload-linker synthesis and conjugation in ADCs development
  • Discover advanced tools and techniques to speed up hit-to-lead transitions and lead optimization
  • Explore case studies that demonstrate successful implementation of discovery strategies
  • Enhance efficiency, reduce attrition, and improve candidate quality through streamlined chemistry workflows

Presenter: Sujay Basu, Ph.D. (Director, Discovery Chemistry, Eurofins Discovery)

Presenter: Matthew Horwitz, Ph.D. (Project Manager & Head of Scale-up Laboratory, Eurofins Discovery)

C&EN
LinkedIn Logo
 

Mohlo by Vás zajímat

Benefits of Agilent Altura Ultra Inert HPLC Column Hardware

Aplikace
| 2026 | Agilent Technologies
Instrumentace
Spotřební materiál, LC kolony
Výrobce
Agilent Technologies
Zaměření
Životní prostředí

Vinylene carbonate water determination via coulometric Karl Fischer titration

Aplikace
| 2026 | Metrohm
Instrumentace
Titrace Karl Fischer, Voltametrie/Coulometrie
Výrobce
Metrohm
Zaměření
Polovodiče

An Isocratic Separation of B Vitamins Using Waters XBridge Biphenyl RP Column with MaxPeak Premier Technology

Aplikace
| 2026 | Waters
Instrumentace
Spotřební materiál, LC kolony
Výrobce
Waters
Zaměření
Farmaceutická analýza

Impurity Monitoring of GLP-1 Therapeutic Peptide RetatrutideUsing a 2D-LC/TOF System

Postery
| 2026 | Agilent Technologies (ASMS)
Instrumentace
LC/MS, LC/MS/MS, LC/TOF, LC/HRMS, 2D-LC
Výrobce
Agilent Technologies
Zaměření
Farmaceutická analýza

Increased sensitivity for low-input label-free proteomics using the Orbitrap Astral MS and μPAC Neo Plus Columns

Aplikace
| 2026 | Thermo Fisher Scientific
Instrumentace
LC/HRMS, LC/Orbitrap, LC/MS, LC/MS/MS
Výrobce
Thermo Fisher Scientific
Zaměření
Proteomika
Další projekty
GCMS
ICPMS
Sledujte nás
FacebookX (Twitter)LinkedInYouTube
Další informace
WebinářeO násKontaktujte násPodmínky užití
LabRulez s.r.o. Všechna práva vyhrazena. Obsah dostupný pod licencí CC BY-SA 4.0 Uveďte původ-Zachovejte licenci.